Marek K - Search Results

1

Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, Borghammer P, Brooks DJ, Pavese N. Qamhawi Z, et al. Among authors: marek k. Brain. 2015 Oct;138(Pt 10):2964-73. doi: 10.1093/brain/awv215. Epub 2015 Jul 23. Brain. 2015. PMID: 26209314

2

Serotonergic dysfunction in depression associated with Parkinson's disease.

McCance-Katz EF, Marek KL, Price LH. McCance-Katz EF, et al. Among authors: marek kl. Neurology. 1992 Sep;42(9):1813-4. doi: 10.1212/wnl.42.9.1813. Neurology. 1992. PMID: 1387464

3

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.

Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C, et al. Seibyl JP, et al. Among authors: marek kl. Ann Neurol. 1995 Oct;38(4):589-98. doi: 10.1002/ana.410380407. Ann Neurol. 1995. PMID: 7574455

4

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, Charney DS, van Dyck C, Hoffer PB, Innis RP. Marek KL, et al. Neurology. 1996 Jan;46(1):231-7. doi: 10.1212/wnl.46.1.231. Neurology. 1996. PMID: 8559382

5

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, Seibyl JP. Innis RB, et al. Among authors: marek kl. Mov Disord. 1999 May;14(3):436-42. doi: 10.1002/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j. Mov Disord. 1999. PMID: 10348466 Clinical Trial.

6

[(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.

Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. Varrone A, et al. Among authors: marek kl. Mov Disord. 2001 Nov;16(6):1023-32. doi: 10.1002/mds.1256. Mov Disord. 2001. PMID: 11748733

7

Single-photon emission tomography and dopamine transporter imaging in Parkinson's disease.

Marek K, Jennings D, Seibyl J. Marek K, et al. Adv Neurol. 2003;91:183-91. Adv Neurol. 2003. PMID: 12442677 Review. No abstract available.

8

Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.

Marek K, Jennings D, Seibyl J. Marek K, et al. Ann Neurol. 2003;53 Suppl 3:S160-6; discussion S166-9. doi: 10.1002/ana.10486. Ann Neurol. 2003. PMID: 12666107 Review. No abstract available.

9

Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa.

Marek K, Jennings D, Seibyl J. Marek K, et al. Neurology. 2003 Sep 23;61(6 Suppl 3):S43-8. doi: 10.1212/wnl.61.6_suppl_3.s43. Neurology. 2003. PMID: 14504379 Review. No abstract available.

10

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.

Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, Prentice R, Shults CW, Stoessl AJ. Brooks DJ, et al. Among authors: marek kl. Exp Neurol. 2003 Nov;184 Suppl 1:S68-79. doi: 10.1016/j.expneurol.2003.08.008. Exp Neurol. 2003. PMID: 14597329 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

456 results

Search Page

Filters